Despite
lowering low - density lipoprotein (LDL), known as «bad»
cholesterol, while
markedly increasing
levels of high - density lipoprotein (HDL), or «good»
cholesterol, a large clinical trial to investigate the
cholesterol drug evacetrapib was discontinued early after a preliminary analysis showed it did not reduce rates of major adverse cardiovascular events, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.